[Pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field. Pediatric Study Group of ME1207]. 1993

R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
Department of Pediatrics, School of Medicine, Teikyo University.

Cefditoren pivoxil (ME1207) in granules, a new oral cephalosporin, was pharmacokinetically and clinically evaluated in the pediatric field and the following results were obtained: 1. Pharmacokinetics In infants administered single oral doses of 3 mg (potency)/kg and 6 mg/kg, the Cmax was 1.54 +/- 0.68 and 2.85 +/- 1.03 micrograms/ml; Tmax, 2.27 +/- 1.08 and 2.06 +/- 1.16 hours; T 1/2, 2.22 +/- 1.95 and 1.68 +/- 0.66 hours; and AUC (0-infinity), 7.43 +/- 3.68 and 11.90 +/- 4.51 micrograms.hr/ml, respectively. These values have indicated that the drug has a dose-dependent pharmacokinetic behavior. Urinary concentrations peaked in 2-4 hours after administration. Urinary recovery rates in the first 8 hours were 19.4 +/- 6.6% at 3 mg/kg and 17.1 +/- 5.2% at 6 mg/kg. 2. Clinical results The clinical efficacy of the drug was evaluated in 445 patients with various infections. Cefditoren pivoxil was administered at daily doses of 9-18 mg/kg divided into 3 equal doses to most patients. Daily doses of > 7.5-10.5 mg/kg were given to 48.8% of the patients. The overall clinical efficacy rate was 97.3%, and this drug was effective in 97.5% of the 319 patients for whom the causative pathogens were identified and in 96.8% of the 126 patients with infections for whom the causative pathogens were unknown. The efficacy rate at daily doses of > 7.5-10.5 mg/kg was 97.2%, similar to that obtained at daily doses of > 10.5-19.5 mg/kg (97.0%). The bacteriological eradication rate was 90.4%. The efficacy and eradication rates for 66 patients who had not responded to previous chemotherapy were 95.5% (63/66) and 89.4%, respectively. Side effects occurred in 19 (4.2%) of 456 patients subjected to safety analyses. The primary side effect was diarrhea but no serious side effects were noted. As abnormal laboratory test results, moderate increases of the eosinophils and platelets counts as well as moderate elevations of the transaminases were observed. These abnormalities are also seen with other cephems and to a similar extent. No particular and serious problems were associated with administration of this drug. Based on the above results, cefditoren pivoxil is considered to be very useful at a dose level of 3 mg/kg t.i.d. against most infections encountered in the pediatric field.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
July 1993, The Japanese journal of antibiotics,
R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
July 1993, The Japanese journal of antibiotics,
R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
April 1994, The Japanese journal of antibiotics,
R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
July 1993, The Japanese journal of antibiotics,
R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
January 1997, Drugs under experimental and clinical research,
R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
July 1993, The Japanese journal of antibiotics,
R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
September 1989, The Japanese journal of antibiotics,
R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
August 1989, The Japanese journal of antibiotics,
R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
February 1994, The Japanese journal of antibiotics,
R Fujii, and H Yoshioka, and A Okuno, and K Fujita, and K Murono, and S Maruyama, and H Sakata, and K Iseki, and Y Wagatsuma, and N Fukushima
December 2013, The Japanese journal of antibiotics,
Copied contents to your clipboard!